Australia Trial Exposes Employee Doubts About Merck Vioxx Handling
This article was originally published in PharmAsia News
Australia's Merck, Sharp & Dohme and its U.S. parent, Merck, were the subjects of more doubts cast in a court trial over their innocence of the consequences of their anti-arthritis drug Vioxx (rofecoxib). Plaintiff attorneys showed the jury in a federal court class action trial e-mail traffic that showed some employees expressed concerns about the drug. One was from an employee who said it was "a bit too much to swallow" that Merck was not aware of the drug's risks years earlier than it has admitted and well before it was withdrawn from the market in 2004. Merck has maintained it acted appropriately and responsibly. (Click here for more
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.